Marco Z.
- Country
- Italy
- Department
- S.C. Oncoematologia Pediatrica
Research Overview
- Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
- Safety, Tolerability, and Feasibility of Rectal MaaT013 (Allogeneic Pooled Fecal Microbiota) in Ruxolitinib‑Refractory Pediatric and Adolescent Gastrointestinal Acute Graft‑Versus‑Host Disease
- International Pediatric Study of Arsenic Trioxide and Tretinoin ± Gemtuzumab Ozogamicin for Acute Promyelocytic Leukemia in Children and Adolescents
Data & Insights
Has run more than one trial at 255 of 396 partner sites.
Specializations
Leukemia Research
Specializes in treating various forms of acute lymphoblastic leukemia, including high-risk cases and specific genetic variants like Philadelphia chromosome-positive ALL. Focuses on innovative treatment approaches for myeloid leukemia, particularly in children with Down syndrome.
- Pediatric ALL treatments
- Novel therapeutic combinations
- Stem cell transplantation
Lymphoma Studies
Conducts research on lymphoblastic lymphoma and Hodgkin lymphoma treatments, with particular emphasis on advanced-stage disease management and novel therapeutic combinations. Explores targeted therapies including brentuximab vedotin for pediatric patients.
- Advanced-stage lymphoma protocols
- Immunotherapy approaches
- Pediatric treatment optimization
Rare Blood Disorders
Investigates treatments for sickle cell disease, thalassemia, and Langerhans Cell Histiocytosis. Leads studies on graft versus host disease management and innovative therapeutic approaches for thrombotic microangiopathy following stem cell transplantation.
- Novel therapeutic agents
- Post-transplant complications
- Long-term treatment outcomes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.